Search results for "hepatitis"

showing 10 items of 1578 documents

Heat Shock Protein 70 Serum Levels Differ Significantly in Patients with Chronic Hepatitis, Liver Cirrhosis, and Hepatocellular Carcinoma

2014

Members of the heat shock protein 70 (HSP70) family play an important role in assisting protein folding, preventing protein aggregation and transport of proteins across membranes under physiological conditions. Following environmental (i.e., irradiation, chemotherapy), physiological (i.e., cell growth, differentiation), and pathophysiological (i.e., inflammation, tumorigenesis) stress, the synthesis of heat shock proteins (HSPs) is highly up-regulated, whereas protein synthesis in general is reduced. In contrast to normal cells, many tumor entities including hepatocellular carcinoma (HCC) overexpress HSP70, the major-stress-inducible member of the HSP70 family, present it on their cell surf…

medicine.medical_specialtyPathologyCirrhosismedicine.medical_treatmentliver cirrhosisImmunologyInflammationmedicine.disease_causeGastroenterology03 medical and health sciencesLiver disease0302 clinical medicineInternal medicinemedicineImmunology and AllergyHCCprognostic biomarker030304 developmental biologyOriginal Research0303 health sciencesChemotherapyserum HSP70business.industryHcc ; Chronic Hepatitis ; Inflammation ; Liver Cirrhosis ; Prognostic Biomarker ; Serum Hsp70medicine.diseasePathophysiology3. Good healthHsp70HCC serum HSP70 prognostic biomarker chronic hepatitis inflammation liver cirrhosisinflammation030220 oncology & carcinogenesisHepatocellular carcinomachronic hepatitismedicine.symptomCarcinogenesisbusinessFrontiers in Immunology
researchProduct

The dilemma for patients with chronic hepatitis C: treat now or warehouse?

2013

Dual therapy with peginterferon and ribavirin, the only treatent for chronic hepatitis C available In Italy and in many other ountries worldwide up to 2013, obtains satisfactory response ates in infections with hepatitis C virus (HCV) genotype 2, but far rom optimal for other genotypes [1,2]. Eradication requires 6–12 onths of therapy, with significant inconvenience for patients: dverse reactions force premature termination in about 20% of atients and reduced the quality of life for almost all who persist n treatment. In view of the important and prolonged side effects, nterferon-based treatment is perceived as a nightmare by many symptomatic,well-being, socially activepatients (the largema…

medicine.medical_specialtyPediatricsTime FactorsProlineHepatitis C virusAlpha interferonmedicine.disease_causeAntiviral AgentsTelaprevirPolyethylene Glycolschemistry.chemical_compoundLiver diseaseBoceprevirDrug DiscoveryRibavirinmedicineHumansProtease InhibitorsAdverse effectWatchful WaitingDrug CarriersHepatologybusiness.industryRibavirinGastroenterologyInterferon-alphaHepatitis C Chronicmedicine.diseaseSurgeryEastern europeanchemistryHCVDrug Therapy CombinationbusinessOligopeptidesmedicine.drugDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Escitalopram for the prevention of peginterferon-alpha2a-associated depression in hepatitis C virus-infected patients without previous psychiatric di…

2012

BACKGROUND: Depression is a major complication during treatment of chronic hepatitis C virus (HCV) infection with interferon-alpha (IFN-alpha). It is unclear whether antidepressants can prevent IFN-induced depression in patients without psychiatric risk factors. OBJECTIVE: To examine whether preemptive antidepressant treatment with escitalopram can decrease the incidence or severity of depression associated with pegylated IFN-alpha in HCV-infected patients without a history of psychiatric disorders. DESIGN: Randomized, multicenter, double-blind, prospective, placebo-controlled, parallel-group trial. (ClinicalTrials.gov registration number: NCT00136318) SETTING: 10 university and 11 academic…

medicine.medical_specialtyPlacebolaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicineInternal MedicinemedicineEscitalopram030212 general & internal medicinePsychiatryDepression (differential diagnoses)business.industryIncidence (epidemiology)Absolute risk reductionGeneral MedicineHepatitis Cmedicine.disease3. Good healthTolerability030211 gastroenterology & hepatologybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologymedicine.drug
researchProduct

Implication of Normal Liver Enzymes in Liver Disease

2009

Summary.  Chronic liver disease is usually asymptomatic until its late stages and also significant hepatic necroinflammation and fibrosis may be present in persistently normal ALT levels HBV, HCV carriers or similarly, in patients with nonalcoholic fatty liver disease. Given the large number of persons in the general population which may harbor a clinically significant liver disease behind the screen of normal alanine aminotransferase, more attention should be devoted to future research for alternative noninvasive markers of liver damage.

medicine.medical_specialtyPopulationChronic liver diseaseaminotransferases chronic hepatitis liver fibrosisGastroenterologySensitivity and SpecificityLiver diseaseVirologyInternal medicineNonalcoholic fatty liver diseasemedicineHumanseducationeducation.field_of_studyHepatologymedicine.diagnostic_testbusiness.industryLiver DiseasesFatty liverAlanine TransaminaseHepatitis Cmedicine.diseaseInfectious DiseasesLiverHepatic fibrosisLiver function testsbusiness
researchProduct

Autoimmunhepatitis und Overlap-Syndrom: Therapie

2002

Die autoimmune Hepatitis (AIH), die primär biliäre Zirrhose (PBC) und die primär sklerosierende Cholangitis (PSC) werden zum Formenkreis der autoimmunen Lebererkrankungen gezählt. Bei diesen Lebererkrankungen spielen Immunreaktionen gegen wirtseigene Antigene eine herausragende pathogenetische Rolle. Lediglich für die AIH ist die autoimmune Ätiologie hinreichend belegt, während für die anderen beiden Erkrankungen zwar Autoimmunphänomene beschrieben wurden, jedoch die Rolle weiterer konditionierender Faktoren und infektiöser Agenzien weiter zu klären sind. Die Autoimmunhepatitis hat unbehandelt eine ungünstige Prognose und muss deshalb so früh wie möglich diagnostiziert und behandelt werden…

medicine.medical_specialtyPrimary biliary cirrhosisbusiness.industryInternal medicinemedicine.medical_treatmentmedicineImmunosuppressionGeneral MedicineAutoimmune hepatitismedicine.diseasebusinessGastroenterologyPrimary sclerosing cholangitisPraxis
researchProduct

Corrigendum to “Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the ‘accordion’ regimen?” [J Hepatol 47 …

2008

medicine.medical_specialtyRegimenHepatologyChronic hepatitisbusiness.industryInternal medicineGenotypemedicinebusinessAccordionProlonged treatmentSurgeryJournal of Hepatology
researchProduct

Estudios de epidemiología molecular en población inmigrante en España

2014

Fundamentos: La epidemiología molecular es una nueva disciplina que permite la integración de la información sobre la variabilidad genética de patógenos infecciosos con su difusión en la población y subgrupos de la misma incluyendo, por ejemplo, las mutaciones de resistencia a antibióticos y antivirales. El objetivo es conocer qué posibles diferencias existe en las características genéticas de los agentes infecciosos que afectan a las poblaciones inmigrante y autóctoctona en España. Métodos: Se revisaron artículos originales publicados entre 1998-2013, con las palabras clave "epidemiología molecular", "tipado molecular", "secuenciación", "inmigrante", "España". Resultados: De un total de 26…

medicine.medical_specialtyResistencia a antibióticosPopulationHuman immunodeficiency virus (HIV)lcsh:Medicinemedicine.disease_causeInmigrantesHepatitisMycobacterium tuberculosisMolecular typingGenetic variationTuberculosisMedicineTypingeducationImmigrant populationGeneticseducation.field_of_studyMolecular epidemiologybiologybusiness.industrylcsh:Public aspects of medicinelcsh:REpidemiología molecularVIHlcsh:RA1-1270General Medicinebiology.organism_classificationSurgerybusinessRevista Española de Salud Pública
researchProduct

Stauffer’s Syndrome in Patient with Metastatic Prostate Cancer

2019

Cholestasis is a symptom that can be present in many conditions, such as bile duct obstruction by malignant mases, obstruction by gallstone, acute and chronic viral hepatitis, and autoimmune disorders, such as primary biliary and sclerosing cholangitis. Stauffer syndrome is a rare type of paraneoplastic syndrome that presents as cholestasis with absence of underlying disease. Classically Stauffer syndrome has been described in renal cell cancer patients. In literature cholestasis as manifestation of paraneoplastic syndrome has also been described in patients with prostate adenocarcinoma and pancreatic and bronchogenic carcinoma. Conclusions. Stauffer syndrome should be kept in mind in patie…

medicine.medical_specialtyS syndromebusiness.industryBile duct030232 urology & nephrologyCase ReportGeneral Medicinemedicine.diseaseStauffer syndromelcsh:Diseases of the genitourinary system. Urologylcsh:RC870-923GastroenterologyBronchogenic carcinoma03 medical and health sciencesProstate cancer0302 clinical medicinemedicine.anatomical_structureCholestasis030220 oncology & carcinogenesisInternal medicinemedicineIn patientbusinessViral hepatitisCase Reports in Urology
researchProduct

Cost-effectiveness of sofosbuvir plus ribavirin with or without pegylated interferon for the treatment of chronic hepatitis C in Italy.

2015

Objective:Across Italy up to 7.3% of the population is infected with hepatitis C virus (HCV), with long-term complications resulting in high medical costs and significant morbidity and mortality. Current treatment options have limitations due to side effects, interferon intolerability and ineligibility, long treatment durations and low sustained virological response (SVR) rates, especially for the most severe patients). Sofosbuvir is the first nucleotide polymerase inhibitor with pan-genotypic activity. Sofosbuvir, administered with ribavirin (RBV) and with or without pegylated interferon (PEG-INF), resulted in >90% SVR across treatment-naïve (TN) genotype (GT) 1-6 patients. It is also t…

medicine.medical_specialtySofosbuvirGenotypeCost effectivenessHepatitis C virusCost-Benefit AnalysisAlpha interferonmedicine.disease_causeGastroenterologyPolyethylene GlycolAntiviral AgentsSeverity of Illness IndexTelaprevirTelaprevirPolyethylene Glycolschemistry.chemical_compoundPegylated interferonBoceprevirInternal medicineQuality-Adjusted Life YearRibavirinmedicineCost-effectiveness analysiHumansCost-Benefit AnalysiAntiviral AgentBoceprevirbusiness.industryHealth PolicyRibavirinInterferon-alphaMarkov ChainHepatitis C ChronicPatient Acceptance of Health CareVirologyChronic hepatitis C infectionMarkov ChainschemistryItalyDrug Therapy CombinationQuality-Adjusted Life YearsSofosbuvirbusinessmedicine.drugHumanJournal of medical economics
researchProduct

Is global elimination of HCV realistic?

2017

The elimination of hepatitis C virus (HCV) has been made possible through the availability of new antiviral drugs which may now be administered to all patients with HCV infection, even those with decompensated cirrhosis. The goal of the World Health Organization (WHO) is to reduce the incidence of chronic hepatitis infection from the current 6-10 million to 0.9 million cases of chronic infections by 2030, and annual deaths from 1.4 million to fewer than 0.5 million. Achieving these targets will require full implementation of epidemiological knowledge of HCV infection, screening and testing practices and strategies to link HCV patients to care. This review will focus on the current state of …

medicine.medical_specialtySustained Virologic ResponseHepatitis C virusCost-Benefit Analysismedicine.disease_causeGlobal HealthWorld Health OrganizationAntiviral AgentsWorld health03 medical and health sciences0302 clinical medicineChronic hepatitisInternal medicineEpidemiologymedicineHumansMass Screening030212 general & internal medicineDisease EradicationIntensive care medicineSubstance Abuse Intravenouslinkage to caredirect antiviral agentHepatologybusiness.industryscreeningIncidence (epidemiology)Hcv clearancevirus diseasesHepatologyPatient Acceptance of Health CareHepatitis Cdigestive system diseases030211 gastroenterology & hepatologybusinessPatient awarenessLiver international : official journal of the International Association for the Study of the Liver
researchProduct